HCCS and Methicillin-Resistant Staphylococcus Aureus Pneumonia: The high prevalence of MLS-B antibiotics resistance observed in this study (overall: 84/100, 84%; MRSA-COC isolates: 43/50, 86%; MRSA-CON isolates: 41/50, 82%) may significantly compromise therapeutic efficacy in both MRSA co-infected COVID-19 pneumonia and MRSA pneumonia cases.